Stockscreener 앱 받기
17.14
6.33%
1.02
시간 외 거래:
17.20
0.06
+0.35%
전일 마감가:
$16.12
열려 있는:
$16.17
하루 거래량:
2.07M
Relative Volume:
1.55
시가총액:
$2.99B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-6.542
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
+16.68%
1개월 성능:
+3.82%
6개월 성능:
-11.74%
1년 성능:
-49.02%
1일 변동 폭
$16.10
$17.35
1주일 범위
$14.78
$17.35
52주 변동 폭
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
17.14 | 2.81B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Visual analytics tools that track Immunovant Inc. performanceMarket Risk Report & Short-Term High Return Ideas - Newser
Real time breakdown of Immunovant Inc. stock performance2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What are the analyst revisions for SWINIs Immunovant Inc. stock a good investment in YEARPortfolio Profit Report & Stepwise Trade Signal Implementation - خودرو بانک
What to do if you’re stuck in Immunovant Inc.Market Activity Summary & Expert Verified Stock Movement Alerts - Newser
Is Immunovant Inc. trending in predictive chart modelsWall Street Watch & Daily Stock Trend Watchlist - Newser
Real time social sentiment graph for Immunovant Inc.Trade Risk Report & Daily Stock Trend Reports - Newser
Is Immunovant Inc. a cyclical or defensive stockAnalyst Downgrade & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Is Immunovant Inc. affected by consumer sentimentChart Signals & Advanced Technical Analysis Signals - خودرو بانک
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN
What’s next for Immunovant Inc. stockWeekly Trend Summary & Trade Opportunity Analysis Reports - خودرو بانک
Is Immunovant Inc. stock good for income investors2025 Bull vs Bear & Accurate Intraday Trading Signals - خودرو بانک
Applying Elliott Wave Theory to Immunovant Inc.Analyst Upgrade & Technical Pattern Based Signals - Newser
Using data tools to time your Immunovant Inc. exitGlobal Markets & Risk Managed Investment Signals - Newser
Is Immunovant Inc. stock entering bullish territoryLayoff News & Community Verified Watchlist Alerts - Newser
Earnings visualization tools for Immunovant Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
Immunovant Inc. stock outlook for YEARPortfolio Performance Summary & Safe Entry Trade Signal Reports - Newser
Risk vs reward if holding onto Immunovant Inc.Bond Market & Daily Technical Forecast Reports - Newser
Immunovant reports promising remission data for Graves’ disease therapy By Investing.com - Investing.com Australia
What is Immunovant Inc.’s book value per shareJuly 2025 Update & Daily Volume Surge Trade Alerts - خودرو بانک
Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - The Globe and Mail
Immunovant’s Batoclimab: A Game-Changer in the Evolving Graves’ Disease Market - AInvest
Momentum divergence signals in Immunovant Inc. chart2025 Buyback Activity & AI Enhanced Trading Alerts - Newser
Is Immunovant Inc. a strong growth stockMarket Volume Summary & Consistent Income Trade Recommendations - خودرو بانک
What machine learning models say about Immunovant Inc.2025 Market Trends & Verified Entry Point Detection - Newser
Immunovant stock rises as Oppenheimer reiterates Outperform on Graves’ data - Investing.com
What institutional flow reveals about Immunovant Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
Combining price and volume data for Immunovant Inc.July 2025 Outlook & Reliable Intraday Trade Plans - Newser
Why Immunovant Stock Blasted Higher Today - AOL.com
Can momentum traders help lift Immunovant Inc.Portfolio Return Report & Verified Chart Pattern Trade Signals - Newser
Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise - MarketScreener
What to expect from Immunovant Inc. in the next 30 daysQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease - MarketScreener
Immunovant Announces Promising Graves’ Disease Study Results - TipRanks
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - The Manila Times
Immunovant reports promising remission data for Graves’ disease therapy - Investing.com
Immunovant Reports Promising Six-Month Off-Treatment Data for Batoclimab in Uncontrolled Graves' Disease Patients - Quiver Quantitative
Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy - Quiver Quantitative
80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan
Intraday pattern recognizer results for Immunovant Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Immunovant Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Volume spikes in Immunovant Inc. stock – what they meanRisk Management & Advanced Technical Signal Analysis - Newser
How to use a screener to detect Immunovant Inc. breakoutsJuly 2025 Rallies & Stepwise Trade Signal Implementation - Newser
Immunovant Inc. stock volume spike explainedWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is now a turning point for Immunovant Inc.2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
What indicators show strength in Immunovant Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - Newser
Using economic indicators to assess Immunovant Inc. potentialMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser
Is Immunovant Inc. stock poised for growthMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser
Long term hold vs stop loss in Immunovant Inc.Layoff News & Expert Approved Momentum Trade Ideas - Newser
Short interest data insights for Immunovant Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
1.40%
자본화:
|
볼륨(24시간):